Amgen’s Lumakras Combo Shows Promising Results in KRAS-mutated NSCLC Early-Stage Trial
Amgen (NASDAQ: AMGN) has announced positive early-stage data for its KRASG12C inhibitor Lumakras (sotorasib) when...
NASDAQ: AMGN
Sandoz Reports H1 2023 Financials with 8% YOY Growth, Separation from Novartis Looms
Switzerland-based Sandoz (SWX: SDZ) has published its financial statements for the first half of 2023,...
Amgen and Horizon Therapeutics Reach Agreement with FTC to Proceed with Acquisition
Amgen (NASDAQ: AMGN) and Horizon Therapeutics (NASDAQ: HZNP) have announced a consent order agreement with...
Cordavis Launches First Biosimilar: Novartis’ Hyrimoz to Compete with Humira
Swiss pharmaceutical giant Novartis (NYSE: NVS) unit Sandoz’s biosimilar product, Hyrimoz (adalimumab), which references AbbVie’s...
Amgen’s Lumakras Faces Full Registration Review by FDA for KRAS-Mutated NSCLC
The US Food and Drug Administration (FDA) is scheduled to review an application submitted by...
Sanofi Misses Out on Acquiring Reata Pharmaceuticals to Biogen in USD 7.3 Billion Deal
Media outlet Bloomberg reported today that France-based Sanofi (NASDAQ: SNY) lost a bidding war to...
Amgen Inc. Reports 7% YOY Revenue Increase in Q2 2023 Financials
US-based biotechnology company Amgen Inc., (NASDAQ: AMGN) has released its financial results for the second...
Major Pharma Companies Pledge Support for 250,000 Genomes Sequencing Project
This week, leading pharmaceutical companies AbbVie (NYSE: ABBV), Amgen (NASDAQ: AMGN), AstraZeneca (AZ; NASDAQ: AZN),...
Luye Pharma’s BA1102 Biosimilar to Xgeva Accepted for CDE Review
China-based Luye Pharma Group (HKG: 2186) has announced that a market approval filing for its...
Amgen Reports Q4 and Full-Year 2022 Financials with Global Sales Growth
US major Amgen (NASDAQ: AMGN) has released its Q4 and full-year 2022 financials. Global sales...
Sino Biopharmaceutical Secures Rights to Biosimilar of Amgen’s Xgeva in China
China-based Sino Biopharmaceutical Ltd (HKG: 1177) has announced that its subsidiary CP Pharmaceutical Qingdao has...
Luye Pharma’s Biosimilar to Amgen’s Xgeva Launched in China
China-based Luye Pharma Group (HKG: 2186) has announced the first prescription of its biosimilar version...